Top-Rated Stocks NASDAQ:QURE uniQure - QURE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure Please log in to your account or sign up in order to add this asset to your watchlist. $20.14 +0.34 (+1.72%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$19.63▼$20.1950-Day Range$18.70▼$22.9252-Week Range$12.52▼$28.25Volume762,725 shsAverage Volume579,830 shsMarket Capitalization$946.22 millionP/E RatioN/ADividend YieldN/APrice Target$55.13 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media uniQure MarketRank™ ForecastAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside173.7% Upside$55.13 Price TargetShort InterestBearish9.26% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$261,748 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.29) to ($3.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.74 out of 5 starsMedical Sector809th out of 996 stocksPharmaceutical Preparations Industry394th out of 484 stocks 3.4 Analyst's Opinion Consensus RatinguniQure has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $55.13, uniQure has a forecasted upside of 173.7% from its current price of $20.14.Amount of Analyst CoverageuniQure has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.26% of the float of uniQure has been sold short.Short Interest Ratio / Days to CoveruniQure has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in uniQure has recently increased by 1.94%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YielduniQure does not currently pay a dividend.Dividend GrowthuniQure does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for QURE. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 1 people have searched for QURE on MarketBeat in the last 30 days. This is a decrease of -93% compared to the previous 30 days.MarketBeat Follows1 people have added uniQure to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, uniQure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $261,748.00 in company stock.Percentage Held by InsidersOnly 3.10% of the stock of uniQure is held by insiders.Percentage Held by Institutions88.03% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for uniQure are expected to grow in the coming year, from ($3.29) to ($3.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of uniQure is -7.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of uniQure is -7.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatiouniQure has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About uniQure (NASDAQ:QURE) StockuniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.Read More Receive QURE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter. Email Address QURE Stock News HeadlinesFebruary 7, 2022 | globenewswire.comuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington's Disease - GlobeNewswireFebruary 7, 2022 | finance.yahoo.comuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s DiseaseApril 2, 2023 | Vantage Point (Ad)What’s At Stake In April is ShockingThe Fed will be meeting on a topic that could change trading forever, and the decision could come as soon as the end of April. But by taking the smartest approach now, you can help shield your assets and work toward your trading goals. Time, as always, is of the essence. Click on this link to see what you need to do right away. February 5, 2022 | washingtonpost.comWith CRISPR gene editing, unique treatments begin to take off for rare diseases - The Washington PostFebruary 4, 2022 | finance.yahoo.comGlobal Gene Therapy for Blood Disorders Market worth US$ 5.79 Billion by 2030 - Exclusive Report by InsightAce Analytic - Yahoo FinanceFebruary 4, 2022 | reuters.comAmazon has a unique inflation problem - ReutersFebruary 3, 2022 | washingtonpost.comTurkey's Recep Tayyip Erdogan is the latest leader to visit Ukraine - The Washington PostFebruary 2, 2022 | forbes.comLooking To Fill Unique Sports Merchandise Void, ‘Official League’ Launches Lifestyle Brand - ForbesApril 2, 2023 | Vantage Point (Ad)What’s At Stake In April is ShockingThe Fed will be meeting on a topic that could change trading forever, and the decision could come as soon as the end of April. But by taking the smartest approach now, you can help shield your assets and work toward your trading goals. Time, as always, is of the essence. Click on this link to see what you need to do right away. February 2, 2022 | bbc.comDeliberate infections give unique Covid insight - BBC NewsJanuary 31, 2022 | pymnts.comWhat Makes the UE’s Digital Markets Act Unique - pymnts.comJanuary 31, 2022 | patriotswire.usatoday.comBill Belichick has unique hiring opportunities if everyone swallows their pride - Patriots WireJanuary 31, 2022 | abcnews.go.comReview: Unique narrator propels 'What the Fireflies Knew' - ABC NewsJanuary 31, 2022 | globenewswire.comUNIUM Produces Unique Influencer NFT in Its Marketplace - GlobeNewswireJanuary 28, 2022 | saintswire.usatoday.comHow Sean Payton helped save the Saints, and build a unique bond with fans - Saints WireJanuary 27, 2022 | forbes.comSmall Business Owners Have A Truly Unique Roth Contribution Opportunity! - ForbesJanuary 27, 2022 | latimes.comThese unique creations for three films had us at hello - Los Angeles TimesJanuary 25, 2022 | 6sqft.com13 unique gift ideas for Valentine's Day - 6SqftJanuary 25, 2022 | latimes.comSAT making big changes: going digital, concise, unique tests - Los Angeles TimesJanuary 24, 2022 | forbes.comA Financial Negative Could Be A Marketing Positive As Seton Hall Showcases Its Program In A Unique Setting - ForbesJanuary 21, 2022 | finance.yahoo.comCrosschq Launches Unique Platform to Source Talent with Candidate Referral Network "Crosschq Recruit" - Yahoo FinanceJanuary 20, 2022 | globenewswire.comSoulful Traveling Unveils Unique Adventures - GlobeNewswireJanuary 20, 2022 | forbes.comBloomberg Strategist: Bitcoin’s ‘Unique Phase’ Will Send Its Price To $100,000 In 2022—Meanwhile Ethereum, BNB, Cardano, Solana Prices Tumble - ForbesJanuary 20, 2022 | forbes.comValentine's Day Gift Guide: Unique Vow Renewal Experiences Around The World - ForbesJanuary 19, 2022 | forbes.comMeet The Female Founder Of A Unique Trading Platform With A Social Spin - ForbesJanuary 18, 2022 | forbes.com10 Years On: How Novikov Is Still One Of London’s Most Unique Dining Spots - ForbesJanuary 18, 2022 | seekingalpha.comuniQure: Betting On Hemophilia-B Cure - Seeking AlphaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive QURE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter. Email Address QURE Company Calendar Last Earnings2/27/2023Today4/02/2023Next Earnings (Estimated)5/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:QURE CUSIPN/A CIK1590560 Webwww.uniqure.com Phone(120) 240-6000Fax31-20-566-9272Employees463Year FoundedN/APrice Target and Rating Average Stock Price Forecast$55.13 High Stock Price Forecast$90.00 Low Stock Price Forecast$24.00 Forecasted Upside/Downside+173.7%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,790,000.00 Net Margins-119.07% Pretax Margin-120.45% Return on Equity-26.28% Return on Assets-18.10% Debt Debt-to-Equity Ratio0.22 Current Ratio6.28 Quick Ratio6.19 Sales & Book Value Annual Sales$106.48 million Price / Sales8.89 Cash FlowN/A Price / Cash FlowN/A Book Value$10.17 per share Price / Book1.98Miscellaneous Outstanding Shares46,980,000Free Float45,526,000Market Cap$946.18 million OptionableOptionable Beta1.19 Key ExecutivesMatt KapustaChief Executive Officer & Executive DirectorPierre CalozChief Operating OfficerChristian KlemtChief Financial OfficerRicardo DolmetschPresident-Research & DevelopmentRichard PorterChief Business OfficerKey CompetitorsBiomea FusionNASDAQ:BMEADay One BiopharmaceuticalsNASDAQ:DAWNBiohavenNYSE:BHVNGemini TherapeuticsNASDAQ:GMTXAmryt PharmaNASDAQ:AMYTView All CompetitorsInsiders & InstitutionsMatthew C KapustaSold 2,521 sharesTotal: $53,924.19 ($21.39/share)Ricardo DolmetschSold 837 sharesTotal: $17,610.48 ($21.04/share)Christian KlemtSold 986 sharesTotal: $21,060.96 ($21.36/share)Pierre CalozSold 990 sharesTotal: $21,116.70 ($21.33/share)Alexander Edward Kuta IIISold 585 sharesTotal: $12,495.60 ($21.36/share)View All Insider TransactionsView All Institutional Transactions QURE Stock - Frequently Asked Questions Should I buy or sell uniQure stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" QURE shares. View QURE analyst ratings or view top-rated stocks. What is uniQure's stock price forecast for 2023? 8 brokerages have issued 1 year target prices for uniQure's shares. Their QURE share price forecasts range from $24.00 to $90.00. On average, they expect the company's stock price to reach $55.13 in the next year. This suggests a possible upside of 173.7% from the stock's current price. View analysts price targets for QURE or view top-rated stocks among Wall Street analysts. How have QURE shares performed in 2023? uniQure's stock was trading at $22.67 at the start of the year. Since then, QURE shares have decreased by 11.2% and is now trading at $20.14. View the best growth stocks for 2023 here. When is uniQure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023. View our QURE earnings forecast. How were uniQure's earnings last quarter? uniQure (NASDAQ:QURE) announced its earnings results on Monday, February, 27th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of ($0.89) by $1.04. The biotechnology company earned $102.75 million during the quarter, compared to analysts' expectations of $55.37 million. uniQure had a negative trailing twelve-month return on equity of 26.28% and a negative net margin of 119.07%. What ETFs hold uniQure's stock? ETFs with the largest weight of uniQure (NASDAQ:QURE) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Invesco S&P SmallCap Health Care ETF (PSCH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), SPDR S&P Biotech ETF (XBI), WisdomTree BioRevolution Fund (WDNA), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Harbor Disruptive Innovation ETF (INNO). What is Matthew Kapusta's approval rating as uniQure's CEO? 8 employees have rated uniQure Chief Executive Officer Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among the company's employees. What other stocks do shareholders of uniQure own? Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Block (SQ) and bluebird bio (BLUE). What is uniQure's stock symbol? uniQure trades on the NASDAQ under the ticker symbol "QURE." How do I buy shares of uniQure? Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is uniQure's stock price today? One share of QURE stock can currently be purchased for approximately $20.14. How much money does uniQure make? uniQure (NASDAQ:QURE) has a market capitalization of $946.18 million and generates $106.48 million in revenue each year. The biotechnology company earns $-126,790,000.00 in net income (profit) each year or ($2.71) on an earnings per share basis. How many employees does uniQure have? The company employs 463 workers across the globe. How can I contact uniQure? uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The official website for the company is www.uniqure.com. The biotechnology company can be reached via phone at (120) 240-6000, via email at investors@uniqure, or via fax at 31-20-566-9272. This page (NASDAQ:QURE) was last updated on 4/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.